Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 24, 2026 | June 26, 2026 |
| Autolus Therapeutics plcAUTL · Entity 1933 | Director | June 29, 2026 | July 01, 2026 |
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Chief Financial Officer | March 28, 2023 | March 30, 2023 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | April 30, 2026 | April 30, 2026 |
| VBI Vaccines Inc/BCVBIV · Entity 111039 | Director | January 27, 2022 | January 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,572 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 41,572 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23 | Direct | 22,714 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
Autolus Therapeutics plc
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 31,667 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29 | Direct | 47,500 |
Reported balance
After 2026-06-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
F2: The RSUs vest in one installment on June 29, 2027.
F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.
Codiak BioSciences, Inc.
Report date March 28, 2023 · Filed March 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-28 transaction · row 1
1 source rowRow 1 · 2023-03-28 · Sale · Disposed 13,412 · Balance 0 |
Hemab Therapeutics Holdings, Inc.
Report date April 30, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2032-03-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The warrant was granted on March 21, 2022 and is fully vested. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2033-08-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The warrant was granted on August 14, 2023 and is fully vested. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on March 21, 2022 and is fully vested.
F2: The warrant was granted on August 14, 2023 and is fully vested.
F3: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
VBI Vaccines Inc/BC
Report date January 27, 2022 · Filed January 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2032-01-27 | Direct | 75,000 |
Reported balance
After 2022-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-27 · Grant · Acquired 75,000 · Balance 75,000 F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2022 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2022 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2022 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2022 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date.
F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jul 1, 2026 20:08 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantShare Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001730463-26-000095 · form4.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:08 UTC | Autolus Therapeutics plc AUTL · Entity 1933 | GrantRestricted Share Units · Derivative | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001730463-26-000095 · form4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:21 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 22,714 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001628280-26-045781 · wk-form4_1782505262.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,714 Underlying: Common Stock · 22,714 shares Expires 2036-06-23 F2 · derivative.exercise_date: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:21 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 15,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-045781 · wk-form4_1782505262.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 25, 2025 Filed Jun 28, 2025 01:11 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 23,105 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001655759-25-000118 · wk-form4_1751073062.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,105 Underlying: Common Stock · 23,105 shares Expires 2035-06-24 F2 · derivative.exercise_date: This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 25, 2025 Filed Jun 28, 2025 01:11 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 16,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000118 · wk-form4_1751073062.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,045 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:54 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 9,070 | $0.00 Strike: $33.90 | $0.00 |
DisclosureSEC source: 0001655759-24-000089 · wk-form4_1717192478.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,070 Underlying: Common Stock · 9,070 shares Expires 2034-05-28 F2 · derivative.exercise_date: This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:54 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 5,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000089 · wk-form4_1717192478.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,020 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:25 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 12,787 | $0.00 Strike: $30.33 | $0.00 |
DisclosureSEC source: 0001655759-23-000060 · wk-form4_1687296337.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Common Stock · 12,787 shares Expires 2033-06-14 F2 · derivative.exercise_date: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:25 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 4,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-23-000060 · wk-form4_1687296337.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,121 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 21:13 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 13,412 | $0.17 | $2,270.65 |
DisclosureSEC source: 0000950170-23-011028 · ownership.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 2,570 | $0.59 | $1,521.95 |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · nonDerivative · entry 4 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,412 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 7,613 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · derivative · entry 6 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,224 Underlying: Common Stock · 7,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F4 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 7,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · nonDerivative · entry 3 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:15 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000899243-23-002753 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2033-01-23 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 21:39 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,880 | $0.58 | $1,081.00 |
DisclosureSEC source: 0000899243-23-002405 · doc4.xml · nonDerivative · entry 2 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,120 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:39 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002405 · doc4.xml · derivative · entry 3 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On January 19, 2022, the reporting person was granted 15,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On January 19, 2022, the reporting person was granted 15,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:39 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002405 · doc4.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:15 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031588 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023. F2 · derivative.expiration_date: On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023. Read SEC document |
| August 17, 2022 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 2,364 | $2.21 | $5,231.30 |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · nonDerivative · entry 2 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,369 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| August 16, 2022 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 7,613 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · derivative · entry 5 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,837 Underlying: Common Stock · 7,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F4 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| August 16, 2022 Filed Feb 21, 2023 21:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 7,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-005697 · doc4.xml · nonDerivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 10,192 | $0.00 Strike: $36.79 | $0.00 |
DisclosureSEC source: 0001209191-22-038555 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 Underlying: Common Stock · 10,192 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 30,450 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007014 · doc4.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 Underlying: Common Stock · 30,450 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 30,450 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F3 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 30,450 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 20,300 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000899243-22-007014 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,300 Underlying: Common Stock · 20,300 shares Expires 2032-02-15 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:31 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 75,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001493152-22-002770 · ownership.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2022 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2022 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-002860 · doc4.xml · derivative · entry 2 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On January 19, 2022, the reporting person was granted 15,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 19, 2022, the reporting person was granted 15,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0000899243-22-002860 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 16:55 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 250,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001493152-21-016365 · ownership.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer granted these options on July 1, 2021 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 1, 2021 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| June 08, 2021 Filed Jun 11, 2021 00:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 7,511 | $0.00 Strike: $78.53 | $0.00 |
DisclosureSEC source: 0001209191-21-039673 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 7,511 shares Expires 2021-06-07 F1 · derivative.exercise_date: This option award was granted on June 8, 2021. The shares underlying the award shall vest in full on June 8, 2022 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:59 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $26.60 | $0.00 |
DisclosureSEC source: 0000899243-21-003322 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2031-01-21 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 22, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001209191-20-036363 · doc4.xml · derivative · entry 1 Bain Linda · CIK 0001578407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option award was granted on June 10, 2020. The shares underlying the award shall vest in equal monthly installments through June 10, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.